Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bicalutamide

FDA-approved product (tablet, oral), marketed as Bicalutamide, Casodex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Bicalutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-androgens
FDA pharmacologic class
Androgen Receptor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bicalutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bicalutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma

    NCT06501911 · start 2025-04-08

    Registered record
    Registry ID
    NCT06501911
    Conditions
    Recurrent Glioblastoma; Recurrent High-grade Glioma
    Interventions
    Bicalutamide; Intensity-modulated radiation therapy (IMRT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2025-04-08
    Completion
    2025-07-17
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Glioblastoma; Recurrent High-grade Glioma
    InterventionBicalutamide; Intensity-modulated radiation therapy (IMRT)
    PhasePhase 1
    Registry statusWithdrawn

  • Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

    NCT06222593 · start 2024-10-01

    Registered record
    Registry ID
    NCT06222593
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Bicalutamide in combination with Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-10-01
    Completion
    2027-07-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionBicalutamide in combination with Sunitinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

    NCT05983198 · start 2023-11-07

    Registered record
    Registry ID
    NCT05983198
    Conditions
    Prostate Cancer
    Interventions
    225Ac-PSMA-R2; 68Ga-PSMA-R2; 68Ga-PSMA-11
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2023-11-07
    Completion
    2031-03-04
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention225Ac-PSMA-R2; 68Ga-PSMA-R2; 68Ga-PSMA-11
    PhasePhase 1
    Registry statusActive not recruiting

  • Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

    NCT05781217 · start 2023-03-14

    Registered record
    Registry ID
    NCT05781217
    Conditions
    Prostate Cancer; Salvage Radiotherapy; Biochemical Recurrence; Androgen Deprivation Therapy; Metastases-free Survival
    Interventions
    triptorelin, goserelin, leuprorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-03-14
    Completion
    2032-12
    Enrolment
    534

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Salvage Radiotherapy; Biochemical Recurrence; Androgen Deprivation Therapy +1 more
    Interventiontriptorelin, goserelin, leuprorelin
    PhasePhase 3
    Registry statusRecruiting

  • Tracer-Guided Surgery for Recurrent Prostate Cancer

    NCT05555017 · start 2023-02-15

    Registered record
    Registry ID
    NCT05555017
    Conditions
    Prostate Cancer
    Interventions
    PSMA-radioguided surgery; ADT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-02-15
    Completion
    2025-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPSMA-radioguided surgery; ADT
    PhasePhase 2
    Registry statusUnknown

  • A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

    NCT05327647 · start 2022-06-23

    Registered record
    Registry ID
    NCT05327647
    Conditions
    Non-Muscle Invasive Bladder Cancer
    Interventions
    Bicalutamide; Control Arm
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-06-23
    Completion
    2026-12-31
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Muscle Invasive Bladder Cancer
    InterventionBicalutamide; Control Arm
    PhasePhase 2
    Registry statusRecruiting

  • Camostat With Bicalutamide for COVID-19

    NCT04652765 · start 2021-02-03

    Registered record
    Registry ID
    NCT04652765
    Conditions
    Covid19; SARS-CoV Infection; Coronavirus Infection
    Interventions
    Camostat Mesilate; Bicalutamide 150 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2021-02-03
    Completion
    2021-09-15
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; SARS-CoV Infection; Coronavirus Infection
    InterventionCamostat Mesilate; Bicalutamide 150 mg
    PhasePhase 1
    Registry statusTerminated

  • Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

    NCT04513717 · start 2021-01-21

    Registered record
    Registry ID
    NCT04513717
    Conditions
    Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    Interventions
    Apalutamide; Bicalutamide; Biospecimen Collection; Bone Scan; Buserelin; Computed Tomography; Degarelix; Flutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Elastography; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy; Relugolix; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-01-21
    Completion
    2038-12-31
    Enrolment
    2,753

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    InterventionApalutamide; Bicalutamide; Biospecimen Collection; Bone Scan +14 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer

    NCT03488810 · start 2020-03-10

    Registered record
    Registry ID
    NCT03488810
    Conditions
    Prostate Cancer
    Interventions
    Radiation Therapy; Apalutamide; Luteinising Hormone Releasing Hormone analog agonist (LHRHa); Non-steroidal anti-androgen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2020-03-10
    Completion
    2026-06-15
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiation Therapy; Apalutamide; Luteinising Hormone Releasing Hormone analog agonist (LHRHa); Non-steroidal anti-androgen
    PhasePhase 3
    Registry statusWithdrawn

  • Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer

    NCT04049747 · start 2019-12-11

    Registered record
    Registry ID
    NCT04049747
    Conditions
    Prostate Cancer; Non-metastatic Prostate Cancer; Prostate Adenocarcinoma
    Interventions
    Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]; Focal therapy; Focal therapy after Finasteride 5Mg tablets for 12 weeks; Focal therapy after Bicalutamide 50Mg tablets for 12 weeks
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-12-11
    Completion
    2023-03-20
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Non-metastatic Prostate Cancer; Prostate Adenocarcinoma
    InterventionRadical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]; Focal therapy; Focal therapy after Finasteride 5Mg tablets for 12 weeks; Focal therapy after Bicalutamide 50Mg tablets for 12 weeks
    PhaseNot applicable
    Registry statusCompleted

  • A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

    NCT03809000 · start 2019-04-15

    Registered record
    Registry ID
    NCT03809000
    Conditions
    Prostate Cancer
    Interventions
    Radiation Therapy; Enzalutamide; Bicalutamide; GnRH analog
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-04-15
    Completion
    2029-09-15
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiation Therapy; Enzalutamide; Bicalutamide; GnRH analog
    PhasePhase 2
    Registry statusActive not recruiting

  • Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

    NCT03650894 · start 2019-04-03

    Registered record
    Registry ID
    NCT03650894
    Conditions
    Breast Neoplasm Female; Breast Cancer; Breast Carcinoma; Breast Tumor
    Interventions
    Nivolumab; Ipilimumab; Bicalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-04-03
    Completion
    2026-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasm Female; Breast Cancer; Breast Carcinoma; Breast Tumor
    InterventionNivolumab; Ipilimumab; Bicalutamide
    PhasePhase 2
    Registry statusActive not recruiting

  • Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

    NCT03358563 · start 2018-01-17

    Registered record
    Registry ID
    NCT03358563
    Conditions
    Prostate Cancer
    Interventions
    Docetaxel; Degarelix; Bicalutamide; Ferumoxytol-enhanced MRI imaging
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2018-01-17
    Completion
    2022-09-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDocetaxel; Degarelix; Bicalutamide; Ferumoxytol-enhanced MRI imaging
    PhaseEarly phase 1
    Registry statusCompleted

  • Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

    NCT03147196 · start 2017-06-27

    Registered record
    Registry ID
    NCT03147196
    Conditions
    Stage I Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma
    Interventions
    Bicalutamide; Laboratory Biomarker Analysis; Questionnaire Administration; Raloxifene Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2017-06-27
    Completion
    2022-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage I Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma
    InterventionBicalutamide; Laboratory Biomarker Analysis; Questionnaire Administration; Raloxifene Hydrochloride
    PhasePhase 2
    Registry statusWithdrawn

  • A Study of Definitive Therapy to Treat Prostate Cancer

    NCT02716974 · start 2016-06

    Registered record
    Registry ID
    NCT02716974
    Conditions
    Prostate Cancer
    Interventions
    Leuprolide Acetate; Bicalutamide; Docetaxel; Prostatectomy; Radiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-06
    Completion
    2022-04
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionLeuprolide Acetate; Bicalutamide; Docetaxel; Prostatectomy +1 more
    PhasePhase 2
    Registry statusCompleted